+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Leukapheresis Market by Product (Devices, Filters, Columns, Disposables), Leukopak (Mobilized, Non-Mobilized), Indication (ALL, NHL, Multiple Myeloma), Application (Research, Therapeutic), End User (Hospitals, Pharma, Biotech) - Global Forecast to 2026

  • PDF Icon

    Report

  • 240 Pages
  • April 2021
  • Region: Global
  • Markets and Markets
  • ID: 5311350

The global leukaphereis products market is projected to reach USD 91 million by 2026 from USD 61 million in 2021, at a CAGR of 8.4% during the forecast period. The leukopaks market is expected to reach USD 662 million by 2026, at a CAGR of 41.9%. Leukopaks are enriched leukapheresis products that contain higher concentrations of leukocytes. The increasing incidence and prevalence of leukemia and growing demand for leukopaks for research applications are some of the factors driving the growth of these markets. However, the high cost of therapeutic leukapheresis andc cellular therapies, stringent donor recruitment criteria, and long procedural time for leukapheresis are restraining the growth of this market to a certain extent.








The leukapheresis disposables segment holds the highest market share, by product, in the leukapheresis products market, in the forecast period.


On the basis of product, the leukapheresis market is broadly segmented into leukapheresis disposables and leukaphersis devices. Leukapheresis devices are further segmented into centrifugal devices and membrane separators. The large share of the leukapheresis disposables segment can be attributed to the recurrent use of disposables during leukapheresis procedures, increasing adoption of leukapheresis products for the collection of leukopaks and isolated PBMCs from leukopaks for research applications, and the increasing adoption of therapeutic leukapheresis procedures.


The centrifugal devices segment to grow at the highest CAGR in the leukapheresis devices market, in the forecast period.


Based on type, the leukapheresis devices market is broadly segmented into centrifugal devices and membrane separators. Centrifugal devices segment is expected to grow at the higest CAGR during the forecast period. The high growth of this segment can be attributed to the increasing installation of centrifugal apheresis devices in hospitals for therapeutic apheresis.


Increasing adoption of leukapheresis products for development of cell-based immunotherapies to promote the growth of this segment in the forecast period.  


Based on application, the leukapheresis products market is segmented into research and therapeutic applications. The research applications segment accounted for the largest share of the leukapheresis products market during the forecast period.  The large share of this segment is attributed to the increasing adoption of leukapheresis products for the development of cell-based immunotherapies and leukapheresis-derived primary cells in drug development.


In the leukapheresis products market by end user segment, blood component providers & blood centers segment holds the highest market share.


On the basis of end user, the leukapheresis products market is segmented into blood component providers & blood centers, academic and research institutes, pharmaceutical & biotechnology companies, hospitals & transfusion centers. Blood component providers & blood centers hold the largest share in this market. The large share of this segment can be attributed to growing demand for leukopaks for the development of CAR T-cell therapies, and the increasing demand for blood components in clinical conditions such as cancer.


In the leukopaks market by type, the diseased leukopaks segment is projected to grow at the highest rate in forecast period.


Based on type, the leukopaks market is segmented into mobilized leukopaks, non-mobilized leukopaks, diseased leukopaks, and isolated PBMCs.  In this segment, the diseased leukopaks segment is projected to register the highest growth during the forecast period. The increasing demand for diseased-state leukopaks for cell interaction studies, drug toxicity studies, preclinical development of cell-based therapeutics, immunotherapy, immune-oncology studies, and regenerative medicine is driving the growth of this segment.  


Acute Lymphocytic Leukemia  holds the largest share in the leukopaks market, by indication, in the forecast period.


Based on indication, the leukopaks market is segmented into acute lymphocytic leukemia, chronic lymphocytic leukemia, non-Hodgkin’s lymphoma, multiple myeloma, hepatocellular carcinoma, pancreatic cancer, and other indications (colorectal cancer, neuroblastoma, breast cancer, and acute myeloid leukemia). The acute lymphocytic leukemia segment accounts for the largest share of the leukopaks market, by indication. The large share of this segment can be attributed to the increasing focus of pharmaceutical companies on the development of leukopak-based cell therapies for the treatment of acute lymphocytic leukemia (ALL) and a high number of CAR T-cell therapy clinical trials for ALL.


Acute Lymphocytic Leukemia  holds the largest share in the leukopaks market, by indication, in the forecast period.


Based on indication, the leukopaks market is segmented into mobilized leukopaks, non-mobilized leukopaks, diseased leukopaks, and isolated PBMCs.  In this segment, the diseased leukopaks segment is projected to register the highest growth during the forecast period. The increasing demand for diseased-state leukopaks for cell interaction studies, drug toxicity studies, preclinical development of cell-based therapeutics, immunotherapy, immune-oncology studies, and regenerative medicine is driving the growth of this segment.  


The pharmaceutical and biotechnology companies segment to grow at the highest CAGR in the leukopaks market, by end user, in the forecast period.


By end user, the leukopaks market is segmented into pharmaceutical & biotechnology companies, contract research organizations, and academic & research institutes. Pharmacuetical and biotechnology companies are projected to grow at the highest CAGR in this market in the forecast period. Thi highest growth rate can be attributed to increasing collaboration of pharmaceutical companies with academic institutes, research centers, and hospitals for new drug development. 


North America holds the largest share in the leukaphereis and  leukopaks market, by region, in the forecast period.


The leukapheresis and leukopaks market is segmented into North America, Europe, Asia Pacific, and Rest of the World. The large share of this region can be attributed to the increasing adoption of leukapheresis products for the development of leukoreduced plasma and leukoreduced RBCs, growing adoption of leukopaks as a source of primary cells for research applications, increasing number of clinical trials for the development of CAR T-cell therapy using leukopaks.


A breakdown of the primary participants for the leukapheresis market referred to for this report is provided below:


  • By Company Type: Tier 1 - 30%, Tier 2 - 25%, and Tier 3 - 45%
  • By Designation: C-level - 40%, Director Level - 35%, and Others - 25%
  • By Region: North America - 36%, Europe - 26%, Asia Pacific - 21%, Rest of the World - 17% 

A breakdown of the primary participants for the leukopaks market referred to for this report is provided below:


  • By Company Type: Tier 1 - 40%, Tier 2 - 38%, and Tier 3 - 22%
  • By Designation: C-level - 40%, Director Level - 35%, and Others - 25%
  • By Region: North America - 39%, Europe - 28%, Asia Pacific - 22%, Rest of the World - 11%

The prominent players in the global leukapheresis and leukopaks market are Asahi Kasei Medical Co. Ltd. (Japan), Fresenius SE & Co. KGaA (Germany), Haemonetics Corporation (US), Terumo BCT, Inc. (US), Macopharma SA (France), Miltenyi Biotec (Germany), Guangzhou Daji Medical Science and Technology Co. Ltd. (China), MEDICA S.p.A (Italy), PuriBlood Medical Co. Ltd. (Taiwan), and Beijing ZKSK Technology Co. Ltd. (China). Some prominent players in the leukopaks market are Charles River Laboratories (US), AllCells, LLC (US), StemExpress, LLC. (US), Caltag Medsystems Limited (UK), Lonza Group AG (Switzerland), ZenBio (US), Precision for Medicine (US), BioIVT (US), Discovery Life Sciences (US), and Intelligent Tissue Group (US).


Research Coverage:


The report analyzes the market for various leukapheresis and leukopaks product and their adoption pattern. It aims at estimating the market size and future growth potential of the global leukapheresis and leukopaks market and different segments such as product, application, indication, end user and region. The report also includes an in-depth competitive analysis of the key players in this market along with their company profiles, product & service offerings, and recent developments.


Reasons to Buy the Report 


The report will enrich established firms as well as new entrants/smaller firms to gauge the pulse of the market, which, in turn, would help them garner a greater share. Firms purchasing the report could use one or any combination of the below-mentioned five strategies for strengthening their market presence.


This report provides insights on the following pointers:


  • Market Penetration: Comprehensive information on the product portfolios offered by the top players in the global leukapheresis products and leukopaks market
  • Product Development/Innovation: Detailed insights on the upcoming trends, R&D activities, and product or service launches in the global leukapheresis products and leukopaks market
  • Market Development: Comprehensive information on the lucrative emerging regions by products, end user, and region
  • Market Diversification: Exhaustive information about new products, growing geographies, and recent developments in the global leukapheresis products and leukopaks market.
  • Competitive Assessment: In-depth assessment of market shares, growth strategies, revenue analysis, and products & services of leading players in the global leukapheresis products and leukopaks market.
Frequently Asked Questions about the Global Leukaphereis Products Market

What is the estimated value of the Global Leukaphereis Products Market?

The Global Leukaphereis Products Market was estimated to be valued at $61 million in 2021.

What is the growth rate of the Global Leukaphereis Products Market?

The growth rate of the Global Leukaphereis Products Market is 8.3%, with an estimated value of $91 million by 2026.

What is the forecasted size of the Global Leukaphereis Products Market?

The Global Leukaphereis Products Market is estimated to be worth $91 million by 2026.

Who are the key companies in the Global Leukaphereis Products Market?

Key companies in the Global Leukaphereis Products Market include Allcells, LLC, Asahi Kasei Corporation, Beijing Zksk Technology Co. Ltd., Bioivt, Caltag Medsystems Limited, Charles River Laboratories International, Inc., Discovery Life Sciences, Fresenius Se & Co. Kgaa and Haemonetics Corporation.

Table of Contents

1 Introduction
1.1 Objectives of the Study
1.2 Market Definition
1.2.1 Inclusions and Exclusions
1.3 Market Scope
1.3.1 Markets Covered
1.3.2 Years Considered for the Study
1.4 Currency
Table 1 Standard Currency Conversion Rates
1.5 Limitations
1.6 Stakeholders
1.7 Summary of Changes
2 Research Methodology
2.1 Research Data
Figure 1 Research Design
2.1.1 Secondary Data
2.1.1.1 Key Data from Secondary Sources
2.1.2 Primary Data
Figure 2 Primary Sources
2.1.2.1 Key Data from Primary Sources
2.1.2.2 Insights from Primary Experts
Figure 3 Breakdown of Primary Interviews: Supply-Side and Demand-Side Participants (Leukapheresis & Leukopaks Market)
Figure 4 Breakdown of Primary Interviews: by Company, Designation, and Region (Leukapheresis Market)
Figure 5 Breakdown of Primary Interviews: by Company Type, Designation, and Region (Leukopaks Market)
2.2 Market Size Estimation: Leukapheresis Market
Figure 6 Supply-Side Market Size Estimation: Revenue Share Analysis
Figure 7 Revenue Share Analysis Illustration
Figure 8 Revenue Analysis of the Top 4 Companies: Leukapheresis Market (2020)
Figure 9 CAGR Projections: Supply-Side Analysis (Leukapheresis Market)
Figure 10 Top-Down Approach
2.3 Market Size Estimation: Leukopaks Market
Figure 11 Volume Estimation of Leukopaks Market
Figure 12 CAGR Projections: Supply-Side Analysis (Leukopaks Market)
Figure 13 Top-Down Approach
2.4 Market Breakdown & Data Triangulation
Figure 14 Market Data Triangulation Methodology
2.5 Market Share Analysis
2.6 Assumptions for the Study
2.7 Risk Assessment
Table 2 Risk Assessment: Leukapheresis & Leukopaks Market
2.8 COVID-19 Health Assessment
2.9 COVID-19 Economic Assessment
2.10 Assessment of the Impact of COVID-19 on the Economic Scenario
Figure 15 Criteria Impacting the Global Economy
Figure 16 Recovery Scenario of the Global Economy
2.11 Assessment of the Impact of COVID-19 on the Economic Scenario in the Leukapheresis and Leukopaks Market
3 Executive Summary
Figure 17 Leukapheresis Products Market, by Type, 2021 Vs. 2026 (USD Million)
Figure 18 Leukapheresis Devices Market, by Type, 2021 Vs. 2026 (USD Million)
Figure 19 Leukapheresis Products Market, by Application, 2021 Vs. 2026 (USD Million)
Figure 20 Leukapheresis Products Market, by End-user, 2021 Vs. 2026 (USD Million)
Figure 21 Leukopaks Market, by Type, 2021 Vs. 2026 (USD Million)
Figure 22 Leukopaks Market, by Indication, 2021 Vs. 2026 (USD Million)
Figure 23 Leukopaks Market, by End-user, 2021 Vs. 2026 (USD Million)
Figure 24 Geographic Snapshot: Leukapheresis Products Market
Figure 25 Geographic Snapshot: Leukopaks Market
4 Premium Insights
4.1 Leukapheresis Products Market Overview
Figure 26 Increasing Incidence and Prevalence of Leukemia to Drive Market Growth
4.2 North America: Leukapheresis Products Market, by Type and Country
Figure 27 Leukapheresis Disposables Commanded the Largest Share of the North American Leukapheresis Products Market in 2020
4.3 Leukapheresis Products Market: Geographic Mix
Figure 28 China to Witness the Highest Growth in the Leukapheresis Products Market During the Forecast Period
4.4 Regional Mix: Leukapheresis Products Market
Figure 29 North America Dominated the Market in 2020
4.5 Leukopaks Market Overview
Figure 30 Favorable Government Support and Rising Demand for Leukopaks in Research Applications to Drive Market Growth
4.6 North America: Leukopaks Market, by Product and Country
Figure 31 Mobilized Leukopaks Commanded the Largest Share of the North American Leukopaks Market in 2020
4.7 Leukopaks Market: Geographic Mix
Figure 32 China to Witness the Highest Growth During the Forecast Period
4.8 Regional Mix: Leukopaks Market
Figure 33 APAC Market to Witness the Highest Growth
5 Market Overview
5.1 Introduction
5.2 Market Dynamics
Figure 34 Leukapheresis Market: Drivers, Restraints, Opportunities, and Challenges
5.2.1 Market Drivers
5.2.1.1 Increasing Incidence and Prevalence of Leukemia
Figure 35 Incidence and Mortality Rates of Leukemia, by Region, 2020
5.2.1.2 Increasing Number of Blood Donations
Table 3 Collection of Whole Blood Units, by Country, 2015-2016 (Million Units)
5.2.1.3 Demand for Leukopaks in Clinical Research
Figure 36 Growth in the Number of Car-T Clinical Trials
5.2.2 Market Restraints
5.2.2.1 High Cost of Therapeutic Leukapheresis and Leukopaks
Table 4 Cost of Leukopaks, by Type
5.2.2.2 Stringent Donor Recruitment Criteria
Table 5 Donor Selection Criteria
Table 6 Frequency of Blood Donations from Healthy Donors
5.2.2.3 Dearth of Skilled Professionals and Low Adoption of Therapeutic Leukapheresis
5.2.2.4 Complications Associated with Therapeutic Leukapheresis
5.2.2.5 Long Procedural Time for Leukapheresis
5.2.2.6 High Cost of Cellular Immunotherapies & Lack of Favorable Reimbursement
5.2.3 Market Opportunities
5.2.3.1 Leukapheresis for Pediatric Patients
5.2.3.2 Emerging Economies and Increasing Investments from Academic Institutes, Pharma-Biotech Companies, and Leading Players
5.2.4 Market Challenges
5.2.4.1 Blood Transfusion Safety in Developing Countries
5.3 Porter's Five Forces Analysis
Figure 37 Porter's Five Forces Analysis (2020): Leukapheresis Market
Table 7 Leukapheresis Market: Porter's Five Forces Analysis
5.3.1 Threat from New Entrants
5.3.2 Threat from Substitutes
5.3.3 Bargaining Power of Suppliers
5.3.4 Bargaining Power of Buyers
5.3.5 Intensity of Competitive Rivalry
5.4 Leukopaks: Pricing Analysis
Table 8 Asp of Non-Mobilized Leukopaks
Table 9 Asp of Mobilized Leukopaks
Table 10 Asp of Mobilized Isolated Cells
5.5 Regulatory Analysis (Leukapheresis Products Market)
5.5.1 North America
5.5.1.1 US
5.5.1.2 Canada
5.5.2 Europe
5.5.3 Asia-Pacific
5.5.3.1 Japan
5.6 Regulatory Analysis (Leukopaks Market)
5.6.1 US
Table 11 List of Fda-Approved Car-T Therapeutics
5.6.2 Europe
5.6.3 Japan
5.6.4 China
5.6.5 India
5.7 Value Chain Analysis
Figure 38 Value Chain: Leukapheresis Market (Leukapheresis Systems)
5.8 Ecosystem Map
Table 12 Leukapheresis Market: Ecosystem
Figure 39 Leukapheresis Market: Ecosystem Map (2020)
5.9 Patent Analysis
5.9.1 Patent Publication Trends in the Leukapheresis Market
Figure 40 Global Patent Publication Trends in the Leukapheresis Market, 2015-2020
5.9.2 Top Applicants (Companies) for Leukapheresis Patents
Figure 41 Top Applicant Companies for Leukapheresis Patents, 2015-2020
5.9.3 Jurisdiction Analysis: Top Applicants (Countries) for Leukapheresis Market Patents
Figure 42 Jurisdiction Analysis: Top Applicant Countries for Leukapheresis Patents, 2015-2020
5.10 Technology Analysis
5.10.1 Key Markets for Import and Export (Trade Analysis for Apheresis-Related Products & Equipment)
5.10.1.1 US
Table 13 Us: Number of Exports Related to Apheresis Products
5.10.1.2 Russia
Table 14 Russia: Number of Exports Related to Apheresis Products
5.10.1.3 China
Table 15 China: Number of Exports Related to Apheresis Products
6 Industry Insights
6.1 Introduction
6.2 Industry Trends
6.2.1 Increasing Number of Collaborations Among Pharma and Biotech Companies
Table 16 Recent Pharma-Biotech Collaborations for Car-T Therapy
6.2.2 Introduction of Customizable Cryopreserved Leukopaks
6.2.3 Use of Leukapheresis in Clinical Trials to Determine Changes in Cellular Immune Profiles in COVID-19 Infections
7 Leukapheresis Products Market, by Type
7.1 Introduction
Table 17 Leukapheresis Products Market, by Type, 2019-2026 (USD Million)
Table 18 Leukapheresis Products Market, by Country, 2019-2026 (USD Million)
7.2 Leukapheresis Disposables
7.2.1 Recurrent Usage and Demand for Disposables Boosting the Growth of this Segment
Table 19 Manufacturers of Leukoreduction Filters
Table 20 Manufacturers of Leukapheresis Columns & Cell Separators
Table 21 Leukapheresis Disposables Market, by Country, 2019-2026 (USD Million)
7.3 Leukapheresis Devices
Table 22 Leukapheresis Devices Market, by Type, 2019-2026 (USD Million)
Table 23 Leukapheresis Devices Market, by Country, 2019-2026 (USD Million)
7.3.1 Centrifugal Devices
7.3.1.1 Increasing Installation of Centrifugal Apheresis Devices in Hospitals for Therapeutic Apheresis to Drive Market Growth
Table 24 List of Centrifugal Apheresis Devices Available in the Market
Table 25 Centrifugal Apheresis Devices Market, by Country, 2019-2026 (USD Million)
7.3.2 Membrane Separators
7.3.2.1 Difficulties in Separating Huge Volumes of Plasma from Milliliters of Whole Blood-A Key Factor Limiting the Adoption of These Devices
Table 26 List of Membrane Separators Available in the Market
Table 27 Membrane Separators Market, by Country, 2019-2026 (USD Million)
8 Leukapheresis Products Market, by Application
8.1 Introduction
Table 28 Leukapheresis Products Market, by Application, 2019-2026 (USD Million)
8.2 Research Applications
8.2.1 Increasing Number of Clinical Trials to Drive the Growth of this Segment
Table 29 Leukapheresis Market for Research Applications, by Country, 2019-2026 (USD Million)
8.3 Therapeutic Applications
8.3.1 Increasing Adoption of Leukapheresis Procedures as a Supportive Treatment in Leukemia to Drive Market Growth
Table 30 Leukapheresis Products Market for Therapeutic Applications, by Country, 2019-2026 (USD Thousand)
9 Leukapheresis Products Market, by End-user
9.1 Introduction
Table 31 Leukapheresis Products Market, by End-user,2019-2026 (USD Million)
9.2 Blood Component Providers & Blood Centers
9.2.1 Blood Component Providers & Blood Centers Are the Largest End-users of Leukapheresis Products
Table 32 Leukapheresis Products Market for Blood Component Providers & Blood Centers, by Country, 2019-2026 (USD Million)
9.3 Academic & Research Institutes
9.3.1 Collaborations Between Pharmaceutical Companies and Academic & Research Institutes Will Drive Market Growth
Table 33 Leukapheresis Products Market for Academic & Research Institutes, by Country, 2019-2026 (USD Million)
9.4 Pharmaceutical & Biotechnology Companies
9.4.1 Increasing Number of Clinical Trials to Drive the Growth of this End-User Segment
Table 34 Leading Pharma-Biotech Companies Involved in the Development of Car T-Cell Technologies
Table 35 Leukapheresis Products Market for Pharmaceutical & Biotechnology Companies, by Country, 2019-2026 (USD Million)
9.5 Hospitals & Transfusion Centers
9.5.1 Growth in the Number of Hospitals Performing Transfusion to Drive Market Growth
Table 36 Leukapheresis Products Market for Hospitals & Transfusion Centers, by Country, 2019-2026 (USD Million)
10 Leukopaks Market, by Type
10.1 Introduction
Table 37 Leukopaks Market, by Type, 2019-2026 (USD Million)
Table 38 Leukopaks Market, by Country, 2019-2026 (USD Million)
10.2 Mobilized Leukopaks
10.2.1 Mobilized Leukopaks Accounted for the Largest Share of the Market
Table 39 Mobilized Leukopaks Market, by Country, 2019-2026 (USD Million)
Table 40 Mobilized Leukopaks Market, by Region, 2019-2026 (Units)
10.3 Non-Mobilized Leukopaks
10.3.1 Low Cost as Compared to Mobilized Leukopaks to Drive Market Growth
Table 41 Comparative Analysis of Mobilized Leukopaks and Non-Mobilized Leukopaks
Table 42 Non-Mobilized Leukopaks Market, by Country, 2019-2026 (USD Million)
Table 43 Non-Mobilized Leukopaks Market, by Region, 2019-2026 (Units)
10.4 Diseased Leukopaks
10.4.1 Rising Adoption of Diseased Leukopaks for Cell Interaction and Drug Toxicity Studies to Drive Market Growth
Table 44 Diseased Leukopaks Market, by Country, 2019-2026 (USD Million)
Table 45 Diseased Leukopaks Market, by Region, 2019-2026 (Units)
10.5 Isolated Pbmcs
10.5.1 Increasing Focus of Researchers on Cell-Based Therapies to Drive Market Growth
Table 46 Isolated Pbmcs Market, by Country, 2019-2026 (USD Million)
Table 47 Isolated Pbmcs Market, by Region, 2019-2026 (Units)
11 Leukopaks Market, by Indication
11.1 Leukopaks Market, by Indication
Figure 43 Global Number of Clinical Trials with Chimeric Antigen Receptor Cells
Table 48 Leukopaks Market, by Indication, 2019-2026 (USD Million)
Table 49 Leukopaks Market for Acute Lymphocytic Leukemia, by Region, 2019-2026 (USD Million)
Table 50 Leukopaks Market for Multiple Myeloma, by Region, 2019-2026 (USD Million)
Table 51 Leukopaks Market for Non-Hodgkin's Lymphoma, by Region, 2019-2026 (USD Million)
Table 52 Leukopaks Market for Chronic Lymphocytic Leukemia, by Region, 2019-2026 (USD Million)
Table 53 Leukopaks Market for Pancreatic Cancer, by Region, 2019-2026 (USD Million)
Table 54 Leukopaks Market for Hepatocellular Carcinoma, by Region, 2019-2026 (USD Million)
Table 55 Leukopaks Market for Other Indications, by Region, 2019-2026 (USD Million)
12 Leukopaks Market, by End-user
12.1 Introduction
Table 56 Leukopaks Market, by End-user, 2019-2026 (USD Million)
12.2 Academic & Research Institutes
12.2.1 Increasing Number of Industry-Academic Partnerships for Conducting Research on Cell-Based Cancer Therapies to Drive Market Growth
Table 57 Leukopaks Market for Academic & Research Institutes, by Country, 2019-2026 (USD Million)
12.3 Pharmaceutical & Biotechnology Companies
12.3.1 Rising Demand for Target Drug Development Utilizing Leukopaks as Starting Material to Drive Market Growth
Table 58 Leukopaks Market for Pharmaceutical & Biotechnology Companies, by Country, 2019-2026 (USD Million)
12.4 Contract Research Organizations
12.4.1 Increasing Sponsorship of Clinical Trials to Drive the Growth of this End-User Segment
Table 59 Leukopaks Market for Contract Research Organizations, by Country, 2019-2026 (USD Million)
13 Geographic Analysis
13.1 Introduction
Figure 44 Leukapheresis Products Market: Geographic Growth Opportunities
Table 60 Leukapheresis Products Market, by Region, 2019-2026 (USD Million)
Figure 45 Leukopaks Market: Geographic Growth Opportunities
Table 61 Leukopaks Market, by Region, 2019-2026 (USD Million)
13.2 North America
Figure 46 North America: Leukapheresis Products Market Snapshot
Table 62 North America: Leukapheresis Products Market, by Country, 2019-2026 (USD Million)
Table 63 North America: Leukapheresis Products Market, by Type, 2019-2026 (USD Million)
Table 64 North America: Leukapheresis Devices Market, by Type, 2019-2026 (USD Million)
Table 65 North America: Leukapheresis Products Market, by Application, 2019-2026 (USD Million)
Table 66 North America: Leukapheresis Products Market, by End-user, 2019-2026 (USD Million)
Table 67 North America: Leukopaks Market, by Country, 2019-2026 (USD Million)
Table 68 North America: Leukopaks Market, by Type, 2019-2026 (USD Million)
Table 69 North America: Leukopaks Market, by Indication, 2019-2026 (USD Million)
Table 70 North America: Leukopaks Market, by End-user, 2019-2026 (USD Million)
13.2.1 US
13.2.1.1 The Presence of a Large Number of Leading Pharmaceutical and Biotechnology Companies to Drive Market Growth in the US
Figure 47 Number of Registered Car Therapy Clinical Trials in the US, 2013-2020
Table 71 US: Key Macroindicators
Table 72 US: Leukapheresis Products Market, by Type, 2019-2026 (USD Million)
Table 73 US: Leukapheresis Devices Market, by Type, 2019-2026 (USD Million)
Table 74 US: Leukapheresis Products Market, by Application, 2019-2026 (USD Million)
Table 75 US: Leukapheresis Products Market, by End-user, 2019-2026 (USD Million)
Table 76 US: Leukopaks Market, by Type, 2019-2026 (USD Million)
Table 77 US: Leukopaks Market, by End-user, 2019-2026 (USD Million)
13.2.2 Canada
13.2.2.1 Rising Prevalence of Blood Cancer to Stimulate Market Growth in Canada
Table 78 Canada: Key Macroindicators
Table 79 Canada: Leukapheresis Products Market, by Type, 2019-2026 (USD Million)
Table 80 Canada: Leukapheresis Devices Market, by Type, 2019-2026 (USD Thousand)
Table 81 Canada: Leukapheresis Products Market, by Application, 2019-2026 (USD Thousand)
Table 82 Canada: Leukapheresis Products Market, by End-user, 2019-2026 (USD Thousand)
Table 83 Canada: Leukopaks Market, by Type, 2019-2026 (USD Million)
Table 84 Canada: Leukopaks Market, by End-user, 2019-2026 (USD Million)
13.3 Europe
Figure 48 Europe: Leukapheresis Products Market Snapshot
Table 85 Europe: Number of Registered Car Therapy Clinical Trials, by Country, 2015-2020
Table 86 Europe: Leukapheresis Products Market, by Country, 2019-2026 (USD Million)
Table 87 Europe: Leukapheresis Products Market, by Type, 2019-2026 (USD Million)
Table 88 Europe: Leukapheresis Devices Market, by Type, 2019-2026 (USD Million)
Table 89 Europe: Leukapheresis Products Market, by Application, 2019-2026 (USD Million)
Table 90 Europe: Leukapheresis Products Market, by End-user, 2019-2026 (USD Million)
Table 91 Europe: Leukopaks Market, by Country, 2019-2026 (USD Million)
Table 92 Europe: Leukopaks Market, by Type, 2019-2026 (USD Million)
Table 93 Europe: Leukopaks Market, by Indication, 2019-2026 (USD Million)
Table 94 Europe: Leukopaks Market, by End-user, 2019-2026 (USD Million)
13.3.1 UK
13.3.1.1 Rising Prevalence of Target Diseases to Drive Market Growth in the UK
Table 95 UK: Key Macroindicators
Table 96 UK: Leukapheresis Products Market, by Type, 2019-2026 (USD Million)
Table 97 UK: Leukapheresis Devices Market, by Type, 2019-2026 (USD Million)
Table 98 UK: Leukapheresis Products Market, by Application, 2019-2026 (USD Thousand)
Table 99 UK: Leukapheresis Products Market, by End-user, 2019-2026 (USD Million)
Table 100 UK: Leukopaks Market, by Type, 2019-2026 (USD Million)
Table 101 UK: Leukopaks Market, by End-user, 2019-2026 (USD Million)
13.3.2 Germany
13.3.2.1 Increasing Research on Cancer Immunotherapies to Drive Market Growth in Germany
Table 102 Germany: Key Macroindicators
Table 103 Germany: Leukapheresis Products Market, by Type, 2019-2026 (USD Million)
Table 104 Germany: Leukapheresis Devices Market, by Type, 2019-2026 (USD Million)
Table 105 Germany: Leukapheresis Products Market, by Application, 2019-2026 (USD Thousand)
Table 106 Germany: Leukapheresis Products Market, by End-user, 2019-2026 (USD Million)
Table 107 Germany: Leukopaks Market, by Type, 2019-2026 (USD Million)
Table 108 Germany: Leukopaks Market, by End-user, 2019-2026 (USD Million)
13.3.3 Spain
13.3.3.1 Rising Focus on the Development of Novel Car T-Cell Therapies to Drive Market Growth
Table 109 Spain: Key Macroindicators
Table 110 Spain: Leukapheresis Products Market, by Type, 2019-2026 (USD Million)
Table 111 Spain: Leukapheresis Devices Market, by Type, 2019-2026 (USD Million)
Table 112 Spain: Leukapheresis Products Market, by Application, 2019-2026 (USD Thousand)
Table 113 Spain: Leukapheresis Products Market, by End-user, 2019-2026 (USD Million)
Table 114 Spain: Leukopaks Market, by Type, 2019-2026 (USD Million)
Table 115 Spain: Leukopaks Market, by End-user, 2019-2026 (USD Million)
13.3.4 Rest of Europe
Table 116 RoE: Leukapheresis Products Market, by Type, 2019-2026 (USD Million)
Table 117 RoE: Leukapheresis Devices Market, by Type, 2019-2026 (USD Million)
Table 118 RoE: Leukapheresis Products Market, by Application, 2019-2026 (USD Million)
Table 119 RoE: Leukapheresis Products Market, by End-user, 2019-2026 (USD Million)
Table 120 RoE: Leukopaks Market, by Type, 2019-2026 (USD Million)
Table 121 RoE: Leukopaks Market, by End-user, 2019-2026 (USD Million)
13.4 Asia-Pacific
Figure 49 APAC: Leukapheresis Products Market Snapshot
Table 122 APAC: Leukapheresis Products Market, by Country, 2019-2026 (USD Million)
Table 123 APAC: Leukapheresis Products Market, by Type, 2019-2026 (USD Million)
Table 124 APAC: Leukapheresis Devices Market, by Type, 2019-2026 (USD Million)
Table 125 APAC: Leukapheresis Products Market, by Application, 2019-2026 (USD Million)
Table 126 APAC: Leukapheresis Products Market, by End-user, 2019-2026 (USD Million)
Table 127 APAC: Leukopaks Market, by Country, 2019-2026 (USD Million)
Table 128 APAC: Leukopaks Market, by Type, 2019-2026 (USD Million)
Table 129 APAC: Leukopaks Market, by Indication, 2019-2026 (USD Million)
Table 130 APAC: Leukopaks Market, by End-user, 2019-2026 (USD Million)
13.4.1 China
13.4.1.1 Market in China to Witness the Highest Growth During the Forecast Period
Figure 50 Number of Car T-Based Clinical Trials Registered in China (2013-2020)
Table 131 China: Key Macroindicators
Table 132 China: Leukapheresis Products Market, by Type, 2019-2026 (USD Million)
Table 133 China: Leukapheresis Devices Market, by Type, 2019-2026 (USD Million)
Table 134 China: Leukapheresis Products Market, by Application, 2019-2026 (USD Million)
Table 135 China: Leukapheresis Products Market, by End-user, 2019-2026 (USD Million)
Table 136 China: Leukopaks Market, by Type, 2019-2026 (USD Million)
Table 137 China: Leukopaks Market, by End-user, 2019-2026 (USD Million)
13.4.2 Japan
13.4.2.1 Several Research Activities in Japan Are Focusing on the Development of Leukopak-Based Cell Therapies
Table 138 Japan: Key Macroindicators
Table 139 Japan: Leukapheresis Products Market, by Type, 2019-2026 (USD Million)
Table 140 Japan: Leukapheresis Devices Market, by Type, 2019-2026 (USD Million)
Table 141 Japan: Leukapheresis Products Market, by Application, 2019-2026 (USD Thousand)
Table 142 Japan: Leukapheresis Products Market, by End-user, 2019-2026 (USD Million)
Table 143 Japan: Leukopaks Market, by Type, 2019-2026 (USD Million)
Table 144 Japan: Leukopaks Market, by End-user, 2019-2026 (USD Million)
13.4.3 Rest of Asia-Pacific
Table 145 Roapac: Leukapheresis Products Market, by Type, 2019-2026 (USD Million)
Table 146 Roapac: Leukapheresis Devices Market, by Type, 2019-2026 (USD Million)
Table 147 Roapac: Leukapheresis Products Market, by Application, 2019-2026 (USD Million)
Table 148 Roapac: Leukapheresis Products Market, by End-user, 2019-2026 (USD Million)
Table 149 Roapac: Leukopaks Market, by Type, 2019-2026 (USD Million)
Table 150 Roapac: Leukopaks Market, by End-user, 2019-2026 (USD Million)
13.5 Rest of the World
Table 151 RoW: Leukapheresis Products Market, by Type, 2019-2026 (USD Million)
Table 152 RoW: Leukapheresis Devices Market, by Type, 2019-2026 (USD Million)
Table 153 RoW: Leukapheresis Products Market, by Application, 2019-2026 (USD Million)
Table 154 RoW: Leukapheresis Products Market, by End-user, 2019-2026 (USD Million)
Table 155 RoW: Leukopaks Market, by Type, 2019-2026 (USD Million)
Table 156 RoW: Leukopaks Market, by Indication, 2019-2026 (USD Million)
Table 157 RoW: Leukopaks Market, by End-user, 2019-2026 (USD Million)
14 Competitive Landscape
14.1 Introduction
Figure 51 Key Developments of Major Players, January 2018-January 2021
Figure 52 Market Evaluation Framework: Partnerships, Agreements, and Collaborations Dominated the Leukapheresis Market During 2018-2021
14.2 Revenue Share Analysis of the Top 4 Market Players
Figure 53 Leukapheresis Market: Revenue Share Analysis of the Top Four Market Players
14.3 Product Footprint Analysis of the Top Players in the Leukapheresis and Leukopaks Markets
Table 158 Company Product Footprint
Table 159 Company Industry Footprint
Table 160 Company Application Footprint
Table 161 Company Region Footprint
14.4 Leukapheresis Market Share (2020)
Table 162 Leukapheresis Market: Degree of Competition
Figure 54 Leukapheresis Market Share, by Key Player (2020)
14.5 Leukopaks Market Share (2020)
Table 163 Leukopaks Market: Degree of Competition
Figure 55 Leukopaks Market Share, by Key Player (2020)
14.6 Competitive Leadership Mapping (Leukapheresis Market)
14.7 Company Evaluation Matrix Definition & Methodology
14.7.1 Stars
14.7.2 Emerging Leaders
14.7.3 Pervasive Players
14.7.4 Participants
Figure 56 Leukapheresis Market: Company Evaluation Matrix, 2020
14.8 Competitive Leadership Mapping for Start-Ups (Leukapheresis Market) (2020)
14.8.1 Progressive Companies
14.8.2 Dynamic Companies
14.8.3 Starting Blocks
14.8.4 Responsive Companies
Figure 57 Leukapheresis Market: SME/Start-Up Company Evaluation Matrix, 2020
14.9 Competitive Leadership Mapping (Leukopaks Market)
14.9.1 Stars
14.9.2 Emerging Leaders
14.9.3 Pervasive Players
14.9.4 Participants
Figure 58 Leukopaks Market: Company Evaluation Matrix (2020)
14.10 Competitive Situations and Trends
Table 164 Product Launches & Approvals (January 2018-January 2021)
Table 165 Deals (January 2018-January 2021)
Table 166 Other Developments (January 2018-January 2021)
15 Company Profiles
15.1 Key Players (Leukapheresis Market)
15.1.1 Asahi Kasei Corporation
Table 167 Asahi Kasei Corporation: Business Overview
Figure 59 Asahi Kasei Corporation: Company Snapshot (2020)
15.1.2 Fresenius Se & Co. Kgaa
Table 168 Fresenius Se & Co. Kgaa: Business Overview
Figure 60 Fresenius Medical Care: Company Snapshot (2019)
Figure 61 Fresenius Kabi: Company Snapshot (2019)
15.1.3 Haemonetics Corporation
Table 169 Haemonetics Corporation: Business Overview
Figure 62 Haemonetics Corporation: Company Snapshot (2018)
15.1.4 Terumo BCT
Table 170 Terumo BCT: Business Overview
Figure 63 Terumo BCT: Company Snapshot (2020)
15.1.5 Macopharma Sa
Table 171 Macopharma Sa: Business Overview
15.1.6 Miltenyi Biotec
Table 172 Miltenyi Biotec: Business Overview
15.2 Other Players (Leukapheresis Market)
15.2.1 Guangzhou Daji Medical Science and Technology Co. Ltd.
Table 173 Guangzhou Daji Medical Science and Technology Co. Ltd.: Business Overview
15.2.2 Medica Spa.
Table 174 Medica Spa: Business Overview
15.2.3 Puriblood Medical Co. Ltd.
Table 175 Puriblood Medical Co. Ltd.: Business Overview
15.2.4 Beijing Zksk Technology Co. Ltd.
Table 176 Beijing Zksk Technology Co. Ltd.: Business Overview
15.3 Key Players (Leukopaks Market)
15.3.1 Allcells, LLC
Table 177 Allcells, LLC: Business Overview
15.3.2 Stemexpress, LLC
Table 178 Stemexpress, LLC: Business Overview
15.3.3 Charles River Laboratories International, Inc.
Table 179 Charles River Laboratories International, Inc.: Business Overview
Figure 64 Charles River Laboratories International, Inc.: Company Snapshot (2019)
Figure 65 Hemacare Corporation: Company Snapshot (2018)
15.3.4 Lonza Group Ag
Table 180 Lonza Group Ag: Business Overview
Figure 66 Lonza Group Ag: Company Snapshot (2019)
15.4 Other Players (Leukopaks Market)
15.4.1 Caltag Medsystems Limited
Table 181 Caltag Medsystems Limited: Business Overview
15.4.2 Zenbio, Inc.
Table 182 Zenbio, Inc.: Business Overview
15.4.3 Precision for Medicine, Inc.
Table 183 Precision for Medicine, Inc.: Business Overview
15.4.4 Bioivt
Table 184 Bioivt: Business Overview
15.4.5 Discovery Life Sciences
Table 185 Discovery Life Sciences: Business Overview
15.4.6 Intelligent Tissue Group
16 Appendix
16.1 Discussion Guide
16.2 Knowledge Store: Subscription Portal
16.3 Available Customizations
16.4 Related Reports
16.5 Author Details

Executive Summary

Companies Mentioned

  • Allcells, LLC
  • Asahi Kasei Corporation
  • Beijing Zksk Technology Co. Ltd.
  • Bioivt
  • Caltag Medsystems Limited
  • Charles River Laboratories International, Inc.
  • Discovery Life Sciences
  • Fresenius Se & Co. Kgaa
  • Guangzhou Daji Medical Science and Technology Co. Ltd.
  • Haemonetics Corporation
  • Intelligent Tissue Group
  • Lonza Group Ag
  • Macopharma Sa
  • Medica Spa.
  • Miltenyi Biotec
  • Precision for Medicine, Inc.
  • Puriblood Medical Co. Ltd.
  • Stemexpress, LLC
  • Terumo BCT
  • Zenbio, Inc.

Methodology

Loading
LOADING...